Physician profile
Chad E Miller
NPI 1538373071
$381,872.30
in general payments reported to CMS, 2019-2025
40 companies · $54K in 2025
The $54K reported for 2025 was more than what 98% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62K · 2020: $28K · 2021: $45K · 2022: $57K · 2023: $68K · 2024: $67K · 2025: $54K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125K · Consulting Fee: $35K · Travel and Lodging: $20K · Food and Beverage: $9,552 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $124,601.25 |
| Consulting Fee | $34,814.75 |
| Travel and Lodging | $20,125.18 |
| Food and Beverage | $9,552.01 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $157,270.80 | 2019-2025 | Uptravi, Opsumit |
| United Therapeutics Corporation | $151,107.11 | 2019-2025 | Tyvaso, Remodulin, Orenitram |
| Bayer Healthcare Pharmaceuticals INC. | $46,083.75 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $12,893.76 | 2022-2025 | Winrevair |
| Chiesi USA, INC. | $8,497.44 | 2025 | |
| Actelion Pharmaceuticals, Ltd | $3,439.41 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $406.06 | 2019-2025 | Andexxa, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $380.39 | 2019-2025 | Nucala |
| Sandoz INC. | $266.73 | 2019-2025 | Treprostinil |
| Insmed, INC. | $219.63 | 2019-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.21 | 2019-2025 | Ofev |
| Ekos Corporation | $112.41 | 2019 | |
| Baxter Healthcare | $98.43 | 2021 | |
| Pfizer INC. | $91.45 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $75.30 | 2019-2020 |
Show all 39 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.